Details

Last Funding Type

Grant

Last Funding Money Raised

$225K

Industries

Biopharma,Biotechnology,Cosmetic Surgery,Landscaping,Medical,Pharmaceutical,Therapeutics

Founded date

Jan 1, 2014

Number Of Employee

1 - 10

Operating Status

Active

Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway.

The company's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathways in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it.

It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel.